Meeting Banner
Abstract #0486

Neurometabolic changes in RRMS: comparison between fingolimod and injectables therapies

Oun Al-iedani1,2, Saadallah Ramadan2,3, Karen Ribbons2, Rodney Lea2, and Jeannette Lechner-Scott2,4,5
1School of Health Sciences, University of Newcastle, Newcastle, Australia, 2Hunter Medical Research Institute, Newcastle, Australia, 3Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia, 4Department of Neurology, John Hunter Hospital, Newcastle, Australia, 5School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

This novel study compares the neurometabolic effects of different DMTs on the MS brain. We evaluated volumetric and neurometabolic changes in RRMS patients on fingolimod(N=52), injectables(N=46) and HCs cohort(N=51). MRS was acquired from PCG and PFC. Compared to HCs, a significant reduction in NAA/tCr were detected in both locations and cohorts. Clinical parameters, MR-volumetrics and neurometabolic concentrations showed no statistically significant differences between RRMS cohorts. MRI metrics and neurometabolites from both locations, showed moderate correlations with cognition, fatigue and memory. This the first study demonstrating that fingolimod and injectable DMTs influence volumetric and neurometabolic profiles of MS-brain similarly.

This abstract and the presentation materials are available to members only; a login is required.

Join Here